NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 42-50

  Periclou, Antonia P ^a   Avramis, Vassilios I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cytosine arabinoside; Nonlinear mixed effects modeling; Pharmacokinetics

Indexed keywords

CYTARABINE; DRUG METABOLITE; URACIL ARABINOSIDE;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEAMINATION; DRUG CLEARANCE; DRUG DISTRIBUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; METHODOLOGY; MODEL; POPULATION MODEL; PRIORITY JOURNAL; ULTRAVIOLET SPECTROPHOTOMETRY;

ADOLESCENT; ADULT; ARABINOFURANOSYLURACIL; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; HALF-LIFE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

EID: 0029797913     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050536     Document Type: Article

References (36)

1. Ellison RR, for the Acute Leukemia Cooperative Group B (1968) Arabinosylcytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507
2. Avramis VI, Biener R, Krailo M, Finkestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS (1987) Biochemical pharmacology of high dose 1-β-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res 47:6786
3. Kremer WB (1975) Cytarabine. Ann inter Med 82:684
4. Momparler RL (1974) A model for the chemotherapy of acute leukemia with 1-β-D-arabniofuranosylcytosine. Cancer Res 34:1775
5. Chabner BA, Hande KR, Drake JC (1979) Ara-C metabolism: implications for drug resistance and drug interactions. Bull Cancer (Paris) 6:89
6. Shipp MA, Takvorina RC, Canellos GP (1984) High-dose cytosine arabinoside Am J Med 77:845
7. Liliemark JO, Plunkett W, Dixon DO (1985) Relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high dose 1-β-D-arabinofuranosylcytosine. Cancer Res 45:5952
8. Donehower RC, Karp JE, Burke PJ (1986) Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 70:1059
9. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantragian H, Keating MJ (1987) Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 47:3005
10. Talley RW, Vaitkevicius VK (1963) Megaloblastosis produced by a cytosine antagonist 1-β-D-arabinofuranosylcytosine. Blood 21:352
11. Kuffe DW, Munroe D, Herrick D, Egan E, Spriggs D (1990) Effects of 1-β-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacol 26:128
12. Skipper HE, Schabel FMJr, Willcox WX (1967) Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosyl cytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother Rep 51:125
13. Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R (1989) Pharmacology studies of 1-β-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optional regimen of loading bolus plus continuous infusion of the drug. Cancer Res 49:241
14. Avramis VI, Mecum RA, Nyce J, Steele DA, Holcenberg J (1989) Pharmacodynamic and DNA methylation studies of high-dose 1-β-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocyte leukemia. Cancer Chemother Pharmacol 24:203
15. Liliemark OJ, Paul CY, Gahrton CG, Peterson CO (1985) Pharmacokinetics of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-β-D-arabinofuranosylcytosine. Cancer Res 45:2773
16. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W (1990) Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia, Leukemia 4:95
17. Creasey WA (1963) Studies on the metabolism of 5-iodo-2′deoxycytidine in vitro. J Biol Chem 238:1772
18. Avramis VI, Powell W (1987b) Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice. Cancer Invest 5(4):293
19. Periclou AP, Avramis VI (1995) Population pharmacokinetics (PPK) analyses of cytosine arabinoside (ara-C) following high dose (HDara-C) and continuous infusion (CI) in pediatric patients with leukemias (abstract). Proc Am Soc Clin Oncol 14:463
20. Avramis VI, Weinberg KI, Siegel SE (1988) Biochemically directed loading bolus (LB) plus continuous infusion (CI) of ara-C regimen in pediatric patients with acute leukemia (ALL) or lymphoma. International Society of Pediatric Oncology (SIOP), XX Meeting, Trondheim, Norway, August 22-28 (1988), p. 127
21. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of highdose systemic cytosine arabinoside. Cancer 48:2577
22. Nand S, Messmore HL Jr, Patel R, Fisher SG, Fisher RI (1986) Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol 4:571
23. Pallavicini MG (1984) Cytosine arabinoside: molecular, pharmacokinetic and cytokinetic considerations. Pharmacol Ther 25:207
24. Ramilo-Torno LV, Avramis VI (1994) Continuous infusion cytosine arabinoside compound by high dose and conventional dose therapy in pediatric patients with relapsed leukemias. J Infus Chemother 4:9
25. Avramis VI, Champagne J, Sato J, Krailo M, Ettinger L, Poplack DG, Finklestein J, Reaman G, Hammond D, Holcenberg JS (1990) Pharmacology and phase I/II trial of fludarabine as a loading bolus and continuous infusion in pediatric patients. Cancer Res 50:7226
26. Avramis VI, Wierzma S, Holcenberg JS, Reaman G, Hammond D, Sato J (1991) Clinical pharmacology of fludarabine phosphate (F-araAMP) followed by cytosine arabinoside in pediatric patients with relapsed leukemia (CCG 0895) (abstract). Proc Am Soc Clin Oncol 10:122
27. Avramis VI, Huang S-H, Holcenberg JS (1991) Drug synergism, antagonism and collateral sensitivity involving genetic changes. In: Chou T-C, Rideout DC (eds) Molecular mechanisms of chemotherapeutic synergism, potentiation and antogonism. Academic Press, Orlando, p 585
28. Yee A, Solorzano M, Kwock R, Avramis VI (1991) Emergence of cytosine arabinoside resistance in vivo and in vitro (abstract). Proc Am Soc Clin Oncol 10:122
29. Karon M, Shirakawa S (1969) The locus of action of 1-β-D-arabinofuranosylcytosine in the cell cycle. Cancer Res 29:687
30. NONMEM Project Group, NONMEM 77, Version IV, Level 2, 1992. University of California at San Francisco
31. Grevel J, Whiting B, Kelman AW, Taylor WB, Bateman DN (1988) Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients. Clin Pharmacokinet 14:52
32. Maitre PO, Vozeh S, Heykants J, Thomson DA, Stanski DR (1987) Population pharmacokinetics of alfentatil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 66:3
33. Weinberg KI, Avramis VI, Lenarsky C, Folk P, Kogut N, Feig S, Parkman R (1988) Variable high-dose cytosine arabinoside (HDara-C) pharmacology in bone marrow transplant (BMT) patients. Proc Am Soc Clin Oncol 7:68
34. Slavin RE, Dias MA, Sara R (1978) Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. Cancer 42:1747
35. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48:2577
36. White JC, Capizzi RL (1991) A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-β-D-arabinofuranosylcytosine phosphorylation in human leukemia cells. Cancer Res 51:2559